Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Operations And Organization (Policies)
- Recent Accounting Pronouncements Affecting the Company (Policies)
Notes Tables
Notes Details

Stock-Based Compensation (Tables)

v3.10.0.1

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2018

Stock-Based Compensation [Abstract]

Summary Of Stock Compensation Expense


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2018		2017		2018		2017
Statement of operations line item:
General and administrative	$	188,920	$	184,914	$	579,924	$	580,812
Research and development		92,562		42,700		265,286		209,194

Total	$	281,482	$	227,614	$	845,210	$	790,006

Schedule Of Assumptions Made In Calculating The Fair Value Of Options



	Nine Months Ended September 30,
	2018		2017
Black-Scholes assumptions
Expected dividend yield	0	%	0	%
Expected volatility	69-72	%	69-79	%
Risk-free interest rate	2.3-2.8	%	1.8-2.0	%
Expected term (in years)	5.5-6 years		5.5-6 years

Summary Of Share-Based Transactions



	Number of Options		Weighted Average Exercise Price	Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding, January 1, 2018	1,814,231	$	5.33	7.1 years	$	53,883
Granted	860,307	$	1.96
Exercised	-	$	-
Expired	(25,000)	$	21.78
Cancelled	(50,500)	$	5.16

Outstanding, September 30, 2018	2,599,038	$	4.06	7.5 years	$	50,870
Exercisable, September 30, 2018	1,345,721	$	5.71	6.1 years	$	-

Summary Of Unvested Shares



	2018
	Number of Options	Weighted Average Fair Value at Grant Date
Unvested at January 1, 2018	727,543	$	2.39
Granted	860,307	$	1.27
Vested	(334,533)	$	2.89
Cancelled	-	$	-

Unvested at September 30, 2018	1,253,317	$	1.49

Summary Of RSU Activity


	Number of RSUs		Weighted Average Grant Date Fair Value
Outstanding, January 1, 2018	47,300	$	1.84
Granted	-	$	-
Vested and Released	(11,825)	$	1.84
Cancelled	-	$	-

Outstanding, September 30, 2018	35,475	$	1.84

- Definition

Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.

+ References

+ Details

Name:	us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure of the changes in outstanding nonvested shares.

+ References

+ Details

Name:	us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.

+ References

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

+ Details

Name:	us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration